Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP companion diagnostic- Strong financial position maintained with approximately $29.